Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Dhathri Ayurveda Pvt Ltd

    Dhathri Group is a leading consumer products and wellness service provider in the Ayurveda segment in Kerala. The company is also engaged in production of Hair Oil,Dandruff oil

  • No Image
    DIL Ltd

    DIL Ltd. (earlier known as Duphar-Interfran Ltd.) operates in the arenas of pharmaceuticals, biotechnology, environmental solutions and other segments including Entertainment an

  • No Image
    Dishman Pharmaceuticals Chemicals Ltd

    Dishman Pharmaceuticals & Chemicals Ltd was incorporated in 1983, is a research-driven pharmaceutical company promoted by Mr. Janmejay Vyas and family. DPCL is primarily engage

  • No Image
    Divis Laboratories Ltd

    Divis Laboratories Ltd was established in the year 1990. It started as a R&D firm with consulting projects. Later it had established its first manufacturing facility in 1995.